Annotation Detail

Information
Associated Genes
EGFR
Associated Variants
EGFR p.Leu858Arg (p.L858R) ( ENST00000275493.7, ENST00000450046.2, ENST00000455089.5 )
EGFR p.Leu858Arg (p.L858R) ( ENST00000275493.7, ENST00000450046.2, ENST00000455089.5 )
Associated Disease
lung adenocarcinoma
Source Database
CIViC Evidence
Description
In a retrospective study of 46 Caucasian, advanced lung adenocarcinoma patients, a patient harboring EGFR L858R mutation was associated with resistance to erlotinib treatment; the patient survived 3.9 months, as compared to the overall 24 months median overall survival of the other patients who were not resistant to erlotinib treatment.
Variant Origin
somatic
Variant Origin
Somatic
Evidence URL
https://civic.genome.wustl.edu/links/evidence_items/4290
Gene URL
https://civic.genome.wustl.edu/links/genes/19
Variant URL
https://civic.genome.wustl.edu/links/variants/33
Evidence Type
Predictive
Disease
Lung Adenocarcinoma
Evidence Direction
Supports
Drug
Erlotinib
Evidence Level
C
Clinical Significance
Sensitivity/Response
Pubmed
27032107
Drugs
Drug NameSensitivitySupported
ErlotinibSensitivitytrue